BioCentury | Nov 26, 2018
Distillery Therapeutics

Transplant

...of organ rejection. TARGET/MARKER/PATHWAY: Apolipoprotein A-1 (APOA1; apoa); mammalian target of rapamycin (mTOR; FRAP; RAFT1); tumor necrosis factor receptor-associated factor...
...Quang Icahn School of Medicine at Mount Sinai Apolipoprotein A-1 (APOA1) (apo(a)) Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1) Tumor necrosis factor (TNF) receptor-associated factor...
BioCentury | Sep 10, 2018
Distillery Therapeutics

Inflammation

...testing the fusion peptide in additional models of contact hypersensitivity. TARGET/MARKER/PATHWAY: Lymphotoxin β receptor (LTBR); tumor necrosis factor receptor-associated factor...
...Maryland School of Medicine, Baltimore, Md. email: jbromberg@som.umaryland.edu Chris Lieu University of Maryland Lymphotoxin beta receptor (LTBR) Tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) Tumor necrosis factor (TNF) receptor-associated factor...
BioCentury | Jan 2, 2018
Distillery Therapeutics

Neurology

...RAC1 inhibitors in additional models of stroke. TARGET/MARKER/PATHWAY: Ras-related C3 botulinum toxin substrate 1 (RAC1); tumor necrosis factor receptor-associated factor...
...Hongliang Li, same affiliation as above email: lihl@whu.edu.cn Hongjiang Li Wuhan University Ras-related C3 botulinum toxin substrate 1 (RAC1) Tumor necrosis factor (TNF) receptor-associated factor...
BioCentury | Dec 13, 2016
Distillery Therapeutics

Cancer

...marrow compared with cytarabine alone. Next steps include testing TIFA inhibitors in additional cancers. TARGET/MARKER/PATHWAY: TRAF...
...National Taiwan University Hospital, Taipei, Taiwan email: hsinanhou@ntu.edu.tw Hongjiang Li Academia Sinica Chang Gung Memorial Hospital National Taiwan University Hospital TRAF...
BioCentury | Oct 6, 2016
Distillery Therapeutics

Therapeutics: TRAF2 and NCK interacting kinase (TNIK)

Cancer INDICATION: Colorectal cancer Cell culture and mouse studies suggest inhibiting TNIK could help treat colorectal cancer. In a human colorectal carcinoma cell line, the TNIK inhibitor NCB-0846 decreased tumor cell colony formation compared with...
BioCentury | Dec 14, 2015
Product Development

Following CoMMpass

...member C (FAM46C) K-Ras (KRAS) Mitotic control homolog (DIS3) Neuroblastoma Ras viral (v-Ras) oncogene (NRAS) Tumor necrosis factor (TNF) receptor-associated factor...
BioCentury | May 7, 2015
Distillery Therapeutics

Therapeutics: MAP kinase kinase kinase 14 (MAP3K14; NIK); tumor necrosis factor (TNF) receptor-associated factor 3 (TRAF3)

...component of the alternative NF-κB pathway inhibitor. TARGET/MARKER/PATHWAY: MAP kinase kinase kinase 14 (MAP3K14; NIK); tumor necrosis factor (TNF) receptor-associated factor...
BioCentury | Feb 27, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity CD40; tumor necrosis factor receptor-associated factor...
BioCentury | Nov 14, 2013
Distillery Therapeutics

Indication: Inflammation

...In mice, the pan-hydroxylase inhibitor prevented Nf-κb activation. Mass spectrometry analysis identified hydroxylated components of tumor necrosis factor receptor-associated factor...
BioCentury | Jun 28, 2012
Distillery Therapeutics

Indication: Cancer

...week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer Tumor necrosis factor receptor-associated factor...
Items per page:
1 - 10 of 24